Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level in Hormone-Refractory Prostate Cancer Cells
| dc.contributor.author | Karabulut, B. | |
| dc.contributor.author | Erten, C. | |
| dc.contributor.author | Gül, M. K. | |
| dc.contributor.author | Cengiz, E. | |
| dc.contributor.author | Karaca, B. | |
| dc.contributor.author | Küçükzeybek, Y. | |
| dc.contributor.author | Görümlü, G. | |
| dc.contributor.author | Atmaca, H. | |
| dc.contributor.author | Uzunoğlu, S. | |
| dc.contributor.author | Şanlı, U. A. | |
| dc.contributor.author | Baran, Yusuf | |
| dc.contributor.author | Uslu, R. | |
| dc.coverage.doi | 10.1016/j.cellbi.2008.11.011 | |
| dc.date.accessioned | 2017-01-26T12:04:46Z | |
| dc.date.available | 2017-01-26T12:04:46Z | |
| dc.date.issued | 2009 | |
| dc.description.abstract | Docetaxel, a semi-synthetic taxane analogue, is used effectively in the treatment of metastatic prostate cancer. Zoledronic acid, the most potent member of bisphosphonates, has shown pleiotropic anti-tumoral effects on prostate cancer cells. We have explored the possible additive/synergistic effects and the apoptotic pathways induced by combination treatment of docetaxel and zoledronic acid in hormone and drug refractory, PC-3 and DU-145 prostate cancer cells. Combination of docetaxel and zoledronic acid synergistically inhibits cell growth in PC-3 and DU-145 cells. Moreover, this effect was due to downregulation of antiapoptotic protein Bcl-2 in PC-3 and DU-145 cells. In conclusion, docetaxel/zoledronic acid combination is potentially a novel and effective approach for the treatment of prostate cancer. | en_US |
| dc.identifier.citation | Karabulut, B., Erten, C., Gül, M. K., Cengiz, E., Karaca, B., Küçükzeybek, Y., Görümlü, G., Atmaca, H., Uzunoğlu, S., Şanlı, U. A., Baran, Y., and Uslu, R. (2009). Docetaxel/zoledronic acid combination triggers apoptosis synergistically through downregulating antiapoptotic Bcl-2 protein level in hormone-refractory prostate cancer cells. Cell Biology International, 33(2), 239-246. doi:10.1016/j.cellbi.2008.11.011 | en_US |
| dc.identifier.doi | 10.1016/j.cellbi.2008.11.011 | |
| dc.identifier.doi | 10.1016/j.cellbi.2008.11.011 | en_US |
| dc.identifier.issn | 1065-6995 | |
| dc.identifier.issn | 1065-6995 | |
| dc.identifier.issn | 1095-8355 | |
| dc.identifier.scopus | 2-s2.0-58749100624 | |
| dc.identifier.uri | http://doi.org/10.1016/j.cellbi.2008.11.011 | |
| dc.identifier.uri | https://hdl.handle.net/11147/2865 | |
| dc.language.iso | en | en_US |
| dc.publisher | John Wiley and Sons Inc. | en_US |
| dc.relation.ispartof | Cell Biology International | en_US |
| dc.rights | info:eu-repo/semantics/openAccess | en_US |
| dc.subject | Zoledronic acid | en_US |
| dc.subject | Prostate cancer | en_US |
| dc.subject | Docetaxel | en_US |
| dc.subject | Bcl-2 | en_US |
| dc.subject | DU-145 | en_US |
| dc.subject | PC-3 | en_US |
| dc.title | Docetaxel/Zoledronic Acid Combination Triggers Apoptosis Synergistically Through Downregulating Antiapoptotic Bcl-2 Protein Level in Hormone-Refractory Prostate Cancer Cells | en_US |
| dc.type | Article | en_US |
| dspace.entity.type | Publication | |
| gdc.author.institutional | Baran, Yusuf | |
| gdc.author.yokid | 119193 | |
| gdc.bip.impulseclass | C4 | |
| gdc.bip.influenceclass | C4 | |
| gdc.bip.popularityclass | C5 | |
| gdc.coar.access | open access | |
| gdc.coar.type | text::journal::journal article | |
| gdc.collaboration.industrial | false | |
| gdc.description.department | İzmir Institute of Technology. Molecular Biology and Genetics | en_US |
| gdc.description.endpage | 246 | en_US |
| gdc.description.issue | 2 | en_US |
| gdc.description.publicationcategory | Makale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı | en_US |
| gdc.description.scopusquality | Q2 | |
| gdc.description.startpage | 239 | en_US |
| gdc.description.volume | 33 | en_US |
| gdc.description.wosquality | Q3 | |
| gdc.identifier.openalex | W2076831756 | |
| gdc.identifier.pmid | 19103299 | |
| gdc.identifier.wos | WOS:000262980300015 | |
| gdc.index.type | WoS | |
| gdc.index.type | Scopus | |
| gdc.index.type | PubMed | |
| gdc.oaire.accesstype | BRONZE | |
| gdc.oaire.diamondjournal | false | |
| gdc.oaire.impulse | 21.0 | |
| gdc.oaire.influence | 4.219129E-9 | |
| gdc.oaire.isgreen | true | |
| gdc.oaire.keywords | Male | |
| gdc.oaire.keywords | Down-Regulation | |
| gdc.oaire.keywords | Antineoplastic Agents | |
| gdc.oaire.keywords | Apoptosis | |
| gdc.oaire.keywords | DNA Fragmentation | |
| gdc.oaire.keywords | Docetaxel | |
| gdc.oaire.keywords | Zoledronic Acid | |
| gdc.oaire.keywords | PC-3 | |
| gdc.oaire.keywords | Cell Line, Tumor | |
| gdc.oaire.keywords | Humans | |
| gdc.oaire.keywords | Bcl-2 | |
| gdc.oaire.keywords | DU-145 | |
| gdc.oaire.keywords | Zoledronic acid | |
| gdc.oaire.keywords | Caspase 7 | |
| gdc.oaire.keywords | Prostate cancer | |
| gdc.oaire.keywords | Diphosphonates | |
| gdc.oaire.keywords | Caspase 3 | |
| gdc.oaire.keywords | Imidazoles | |
| gdc.oaire.keywords | Prostatic Neoplasms | |
| gdc.oaire.keywords | Drug Synergism | |
| gdc.oaire.keywords | Proto-Oncogene Proteins c-bcl-2 | |
| gdc.oaire.keywords | Drug Resistance, Neoplasm | |
| gdc.oaire.keywords | Androgens | |
| gdc.oaire.keywords | Taxoids | |
| gdc.oaire.popularity | 2.9248863E-9 | |
| gdc.oaire.publicfunded | false | |
| gdc.oaire.sciencefields | 03 medical and health sciences | |
| gdc.oaire.sciencefields | 0302 clinical medicine | |
| gdc.openalex.collaboration | National | |
| gdc.openalex.fwci | 2.50816711 | |
| gdc.openalex.normalizedpercentile | 0.88 | |
| gdc.opencitations.count | 39 | |
| gdc.plumx.crossrefcites | 34 | |
| gdc.plumx.mendeley | 21 | |
| gdc.plumx.pubmedcites | 16 | |
| gdc.plumx.scopuscites | 47 | |
| gdc.scopus.citedcount | 47 | |
| gdc.wos.citedcount | 38 | |
| relation.isAuthorOfPublication.latestForDiscovery | 7bb863bb-9384-4a07-9fbb-b9c1ab7634a3 | |
| relation.isOrgUnitOfPublication.latestForDiscovery | 9af2b05f-28ac-4013-8abe-a4dfe192da5e |